Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006343 · ClinicalTrials.gov registry record · Phase 3
STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
A Phase 3 study of Leukemia, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 1
- Study location
NCT00006343 is a Phase 3 study of Leukemia that has completed, run by Novartis. The trial reports 1 study location across 1 state.
The verdict
NCT00006343, a Phase 3 study of Leukemia, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Biological therapies such as interferon-alfa and STI571 may interfere with the growth of cancer cells. It is not yet known if STI571 is more effective than interferon alfa plus cytarabine for chronic myelogenous leukemia. PURPOSE: Randomized phase III trial to compare the effectiveness of STI571 with that of interferon alfa plus cytarabine in treating patients who have newly diagnosed chronic myelogenous leukemia.
Conditions Studied
Interventions
- DRUG imatinib mesylate
- DRUG cytarabine
- BIOLOGICAL recombinant interferon alfa
Study Locations (1)
New Jersey
- Novartis Pharmaceuticals Corporation - East Hanover
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-06 |
| Est. Completion | 2007-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006343
The ClinicalTrials.gov registry entry for NCT00006343 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 3 interventions - of which imatinib mesylate is the first listed.
NCT00006343 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT00006343 about?
NCT00006343 is a clinical study titled "STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia". RATIONALE: Biological therapies such as interferon-alfa and STI571 may interfere with the growth of cancer cells. It is not yet known if STI571 is more effective than interferon alfa plus cytarabine for chronic myelogenous leukemia. PURPOSE: Randomized phase III trial to compare the effectiveness o...
What is the current status of trial NCT00006343?
This trial is currently completed. It is a Phase 3 study. The study started on 2000-06. Estimated completion is 2007-03.
What conditions does trial NCT00006343 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT00006343?
The interventions under investigation include: imatinib mesylate (DRUG), cytarabine (DRUG), recombinant interferon alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00006343?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006343 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
RECRUITING · Phase 3
-
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 3
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
-
Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria
COMPLETED · Phase 3
-
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
COMPLETED · Phase 3
-
S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.